Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Of the patients, 1308 (52.5%) were male and 1183 (47.5%) were female.Comparison of laboratory parameters between deceased and recovered patients infected with COVID-19VariablesDeceased patients (n = 1149)Recovered patients (n = 1342)P-valueMean age ± SD59.3 ± 10.951.0 ± 13.0< 0.001*Gender (male/female)611/538 (53.2/46.8%)697/645 (51.9/48.1%)0.537ALT, IU/L (mean ± SD) (Reference range: 5 to 40)44.5 ± 23.933.2 ± 24.3< 0.001*AST, IU/L (mean ± SD) (Reference range: 5 to 40)36.9 ± 13.031.3 ± 15.7< 0.001*ALP, IU/L (mean ± SD) (Reference range: up to 306)201.9 ± 66.3171.0 ± 90.6< 0.001*Cholesterol, mg/dL (mean ± SD) (Reference range: 50 to 200)116.6 ± 38.9121.8 ± 36.3< 0.001*TG, mg/dL (mean ± SD) (Reference range: 60 to 165)116.6 ± 41.7131.5 ± 61.5< 0.001*LDL, mg/dL (mean ± SD) (Reference range: up to 150)70.2 ± 35.6107.1 ± 49.3< 0.001*HDL, mg/dL (mean ± SD) (Reference range: > 40)30.6 ± 10.934.4 ± 11.6< 0.001*WBC, 109/L (mean ± SD) (Reference range: 4000 to 10,000)7544.4 ± 2663.47717.4 ± 2897.60.347CRP, mg/L (mean ± SD) (Reference range: < 10 mg/L Negative)67.3 ± 21.456.9 ± 20.9< 0.001*ESR, mm/1st h (mean ± SD) (Reference range: 0 to 15)54.5 ± 15.646.5 ± 15.3< 0.001*FBS, mg/dL (mean ± SD) (Reference range: 70 to 100)110.7 ± 42.9105.6 ± 41.3< 0.001*Platelets × 1000/cumm (mean ± SD) (Reference range: 140,000 to 400,000)186 ± 76185 ± 650.206Uric acid, mg/dL (mean ± SD) (Reference range: 3.6 to 6.8)3.9 ± 1.25.6 ± 1.4< 0.001*Creatinine, mg/dL (mean ± SD) (Reference range: 0.6 to 1.4)1.2 ± 0.30.7 ± 0.2< 0.001*T3, ng/dL (mean ± SD) (Reference range: 2.3 to 4.2)3.1 ± 1.22.5 ± 0.80.061T4, mcg/dL (mean ± SD) (Reference range: 5.6 to 13.7)8.9 ± 4.68.3 ± 3.30.091TSH, mu/L (mean ± SD) (Reference range: 0.4 to 4.5)3.5 ± 1.43.3 ± 1.20.38425-hydroxy vitamin D, ng/mL (mean ± SD) (Normal range: 21 to 150)25.3 ± 10.135.9 ± 13.4< 0.001*SARS-CoV-2 variants< 0.001* Alpha396 (48.1%)427 (51.9%) Delta664 (75.3%)218 (24.7%) Omicron BA.589 (11.2%)697 (88.8%)IFITM3 rs6598045< 0.001* AA190 (17.5%)897 (82.5%) AG508 (60.6%)330 (39.4%) GG451 (79.7%)115 (20.3%)COVID-19 coronavirus disease 2019, ALT alanine aminotransferase, AST aspartate aminotransferase, ALP alkaline phosphatase, TG triglyceride, LDL low density lipoprotein, HDL high density lipoprotein, WBC white blood cells, CRP C-reactive protein, ESR erythrocyte sedimentation rate, FBS fasting blood glucose, T3 triiodothyronine, T4 thyroxine, TSH thyroid-stimulating hormone, SD standard deviation, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2, IFITM3 interferon-induced transmembrane protein 3.*Statistically significant (< 0.05)
Source: Characteristics of patients. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Only 2,491 participants out of a total of 12,316 patients were considered eligible to participate in the study according to inclusion criteria: (1) providing consent before taking part in the study; (2) having same ethnic background and Iranian nationality; (3) having positive rtReal time-PCR test results and being selected from only one hospital; (4) The patients had no previous history of SARS-CoV-2 infection; (5) having no underlying comorbidities such as chronic obstructive pulmonary disease, cystic fibrosis, cancer, pregnancy, human immunodeficiency virus (HIV), obesity, heart disease, kidney disease, liver disease, and diabetes.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Increased risk of COVID-19 mortality rate in IFITM3 rs6598045 G allele carriers infected by SARS-CoV-2 delta variant
Study design awaiting verification · Human Genomics · 2022
Original publication title
Increased risk of COVID-19 mortality rate in IFITM3 rs6598045 G allele carriers infected by SARS-CoV-2 delta variant
© The Author(s) 2022
Original publication · Publisher record · CC BY 4.0 · CC0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
The interferon-induced transmembrane-protein 3 (IFITM3) is a vital component of the immune system's defense against viral infection. Variants in the IFITM3 gene have been linked to changes in expression and the risk of severe Coronavirus disease 2019 (COVID-19). This study aimed to investigate whether IFITM3 rs6598045, quantitative polymerase chain reaction (qPCR) cycle threshold (Ct) values, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants are associated with an increased mortality rate of COVID-19.
Source: BackgroundAbstract: What methods does the paper describe?
The genotyping of IFITM3 rs6598045 polymorphism was analyzed using the amplification refractory mutation system-polymerase chain reaction in 1342 recovered and 1149 deceased patients positive for SARS-CoV-2.
Source: MethodsAbstract: Results
In this study, IFITM3 rs6598045 G allele as minor allele frequency was significantly more common in the deceased patients than in the recovered ones. Furthermore, the highest mortality rates were observed in Delta variant and lowest qPCR Ct values. COVID-19 mortality was associated with IFITM3 rs6598045 GG and AG in Delta variant and IFITM3 rs6598045 AG in Alpha variant. A statistically significant difference was observed in the qPCR Ct values between individuals with GG and AG genotypes and those with an AA genotype.
Source: ResultsAbstract: Conclusion
A possible correlation was observed between the mortality rate of COVID-19, the G allele of IFITM3 rs6598045, and SARS-CoV-2 variants. However, large-scale research is still required to validate our results.
Source: ConclusionAuthors’ abstract
Background
The interferon-induced transmembrane-protein 3 (IFITM3) is a vital component of the immune system's defense against viral infection. Variants in the IFITM3 gene have been linked to changes in expression and the risk of severe Coronavirus disease 2019 (COVID-19). This study aimed to investigate whether IFITM3 rs6598045, quantitative polymerase chain reaction (qPCR) cycle threshold (Ct) values, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants are associated with an increased mortality rate of COVID-19.
Methods
The genotyping of IFITM3 rs6598045 polymorphism was analyzed using the amplification refractory mutation system-polymerase chain reaction in 1342 recovered and 1149 deceased patients positive for SARS-CoV-2.
Results
In this study, IFITM3 rs6598045 G allele as minor allele frequency was significantly more common in the deceased patients than in the recovered ones. Furthermore, the highest mortality rates were observed in Delta variant and lowest qPCR Ct values. COVID-19 mortality was associated with IFITM3 rs6598045 GG and AG in Delta variant and IFITM3 rs6598045 AG in Alpha variant. A statistically significant difference was observed in the qPCR Ct values between individuals with GG and AG genotypes and those with an AA genotype.
Conclusion
A possible correlation was observed between the mortality rate of COVID-19, the G allele of IFITM3 rs6598045, and SARS-CoV-2 variants. However, large-scale research is still required to validate our results.
Supplementary Information
The online version contains supplementary material available at 10.1186/s40246-022-00434-8.
Publication and source details
Original title: Increased risk of COVID-19 mortality rate in IFITM3 rs6598045 G allele carriers infected by SARS-CoV-2 delta variant
Melika Gholami; Fatemeh Sakhaee; Fattah Sotoodehnejadnematalahi; Mohammad Saber Zamani; Iraj Ahmadi; Enayat Anvari; Abolfazl Fateh
Human Genomics · 2022
© The Author(s) 2022https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T21:45:56.194534+00:00
DOI: 10.1186/s40246-022-00434-8 · PMC9675951